Business Context and Reporting Period
This Form 8-K Current Report was filed by Autolus Therapeutics Plc on December 2, 2025, covering events occurring on December 1, 2025. The filing primarily addresses corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel appointments and associated compensation terms.
Material Changes
The material change reported is the appointment of Ryan Richardson as a Class I director, effective December 1, 2025. His term continues until the 2028 annual general meeting or until a successor is elected. Mr. Richardson brings over 20 years of experience in healthcare and investment banking, including a recent tenure as Chief Strategy Officer at BioNTech SE.
Guidance, Outlook, and Compensation Details
The filing outlines the compensatory arrangements for the new director:
- Annual Retainer: £33,000.
- Equity Award: One-time grant of options to purchase 80,000 American Depositary Shares (ADSs).
- Exercise Price: $1.41 per ADS (closing price on November 28, 2025).
- Vesting Schedule: 36 equal monthly installments, contingent on continued service.
No forward-looking guidance, operational outlook, or discussion of risks and contingencies is provided in this specific filing.
Investor Verification Checklist
- Verify the effective date of Ryan Richardson's directorship (December 1, 2025).
- Confirm the total equity grant size (80,000 ADS options) and the exercise price ($1.41).
- Review the vesting schedule (36 months) to understand future dilution implications.
- Check for any potential conflicts of interest given Mr. Richardson's recent role at BioNTech SE.